Ospedale San Raffaele S.r.l.

Fondazione Centro San Raffaele

Science Park Raf S.p.a.

Giulia Casorati

Paolo Dellabona

Claudia De Lalla

Claudio Garavaglia

Michela Consonni

The present invention relates to a TCR or functional variant thereof having antigenic specificity for CD1c molecules associated with a self-lipid, preferably (mLPA) or derivative thereof, to relative polypeptide, protein, nucleic acid, recombinant expression vector, host cell, population of cells, antibody and pharmaceutical composition. The present invention also relates to the uses of said TCR and relative products, in particular for use in the treatment and/or prevention of an hematological disorder.

TCR and uses thereof

A method for the production of activated tumor-specific T cells by co-cultivating, ex vivo, tumor cells from a patient with T cells from that patient, comprising the steps of: i) incubating the tumor cells with a first fusion protein obtained from a B7 protein and one partner of a biological binding pair and a second fusion protein obtained from an antibody against a cell surface antigen and the other partner of the biological binding pair, ii) inhibiting the proliferation of the tumor cells prior to or after that incubation; iii) co-cultivating the tumor cells with the T cells to be activated, until activation of the T cells is attained; iv) separating the activated T cells from the tumor cells, is highly efficient and can be carried out in a simple manner.

Method for the production of activated marked tumor-specific T cells and use thereof in treatment of tumors

Growing community of inventors

Milan, Italy

Giulia Casorati